Source Post
The Only Pharma Stock I’d Go Near Part 2
Nov 28, 2025
The creator analyzes Eli Lilly (LLY), highlighting its strong revenue growth driven by GLP-1 drugs, impressive profit expansion, and healthy free cash flow. Despite a high P/E ratio, the creator is impressed by the company's financial performance and dividend growth, making it the only pharmaceutical stock they would consider investing in.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.